Andexanet Alfa for Acute Bleeding During Treatment With Enoxaparin

Haaps, Thijs F. van; Benz, Alexander P; Xu, Lizhen; Coppens, Michiel; Eikelboom, John W.; Milling, Truman J.; Crowther, Mark; Beyer‐Westendorf, Jan; Cohen, Alexander T.; Yue, Patrick; Conley, Pamela B.; Lu, Genmin; Connolly, Stuart J.

doi:10.1016/s0735-1097(21)03212-5

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[25][26][27][28][29][30][31] van Haaps et al reported that patients with MBE on enoxaparin who received an andexanet bolus of 400 or 800 mg had decreased anti-Xa activity and either excellent or good hemostasis at 12 hours in 87.5% of patients, with thrombotic events within 30 days in 4.5% of patients. 32 Ciraparantag is a small molecule that binds to heparins and DOACs through noncovalent charge-charge interactions. In animal bleeding models it reduces blood loss after tail transection in rats treated with heparin (UFH, LMWH).…”

Section: Specific Reversal Agents For Heparinsmentioning

confidence: 99%

A Historical Perspective on the Reversal of Anticoagulants

Salter

Crowther

2022

Semin Thromb Hemost

Self Cite

View full text Add to dashboard Cite

There has been a landmark shift in the last several decades in the management and prevention of thromboembolic events. From the discovery of parenteral and oral agents requiring frequent monitoring as early as 1914, to the development of direct oral anticoagulants (DOACs) that do not require monitoring or dose adjustment in the late 20th century, great advances have been achieved. Despite the advent of these newer agents, bleeding continues to be a key complication, affecting 2 to 4% of DOAC-treated patients per year. Bleeding is associated with substantial morbidity and mortality. Although specific reversal agents for DOACs have lagged the release of these agents, idarucizumab and andexanet alfa are now available as antagonists. However, the efficacy of these reversal agents is uncertain, and complications, including thrombosis, have not been adequately explored. As such, guidelines continue to advise the use of nonspecific prohemostatic agents for patients requiring reversal of the anticoagulant effect of these drugs. As the indications for DOACs and the overall prevalence of their use expand, there is an unmet need for further studies to determine the efficacy of specific compared with nonspecific pro-hemostatic reversal agents. In this review, we will discuss the evidence behind specific and nonspecific reversal agents for both parenteral and oral anticoagulants.

show abstract